vs
Antero Midstream Corp（AM）とANI PHARMACEUTICALS INC（ANIP）の財務データ比較。上の社名をクリックして会社を切り替えられます
Antero Midstream Corpの直近四半期売上が大きい（$291.1M vs $247.1M、ANI PHARMACEUTICALS INCの約1.2倍）。Antero Midstream Corpの純利益率が高く（41.5% vs 11.1%、差は30.3%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -7.3%）。Antero Midstream Corpの直近四半期フリーキャッシュフローが多い（$186.9M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 3.9%）
Antero Midstream Corpは米国のエネルギー企業で、デラウェア州に法人登録され、本社をコロラド州デンバーに置く。同社の石油・天然ガス埋蔵量は全てアパラチア盆地にあり、水圧破砕技術を用いて採掘を行っている。
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
AM vs ANIP — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $291.1M | $247.1M |
| 純利益 | $120.7M | $27.5M |
| 粗利率 | — | — |
| 営業利益率 | 60.9% | 14.1% |
| 純利益率 | 41.5% | 11.1% |
| 売上前年比 | -7.3% | 29.6% |
| 純利益前年比 | 2.1% | 367.5% |
| EPS（希薄化後） | $0.25 | $1.14 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $291.1M | — | ||
| Q4 25 | $297.0M | $247.1M | ||
| Q3 25 | $294.8M | $227.8M | ||
| Q2 25 | $305.5M | $211.4M | ||
| Q1 25 | $291.1M | $197.1M | ||
| Q4 24 | $287.5M | $190.6M | ||
| Q3 24 | $269.9M | $148.3M | ||
| Q2 24 | $269.8M | $138.0M |
| Q1 26 | $120.7M | — | ||
| Q4 25 | $51.9M | $27.5M | ||
| Q3 25 | $116.0M | $26.6M | ||
| Q2 25 | $124.5M | $8.5M | ||
| Q1 25 | $120.7M | $15.7M | ||
| Q4 24 | $111.2M | $-10.3M | ||
| Q3 24 | $99.7M | $-24.2M | ||
| Q2 24 | $86.0M | $-2.3M |
| Q1 26 | 60.9% | — | ||
| Q4 25 | 33.8% | 14.1% | ||
| Q3 25 | 61.2% | 15.9% | ||
| Q2 25 | 61.0% | 6.6% | ||
| Q1 25 | 60.9% | 13.3% | ||
| Q4 24 | 61.8% | -2.3% | ||
| Q3 24 | 60.2% | -13.8% | ||
| Q2 24 | 56.6% | 3.7% |
| Q1 26 | 41.5% | — | ||
| Q4 25 | 17.5% | 11.1% | ||
| Q3 25 | 39.3% | 11.7% | ||
| Q2 25 | 40.8% | 4.0% | ||
| Q1 25 | 41.5% | 8.0% | ||
| Q4 24 | 38.7% | -5.4% | ||
| Q3 24 | 37.0% | -16.3% | ||
| Q2 24 | 31.9% | -1.7% |
| Q1 26 | $0.25 | — | ||
| Q4 25 | $0.11 | $1.14 | ||
| Q3 25 | $0.24 | $1.13 | ||
| Q2 25 | $0.26 | $0.36 | ||
| Q1 25 | $0.25 | $0.69 | ||
| Q4 24 | $0.23 | $-0.45 | ||
| Q3 24 | $0.21 | $-1.27 | ||
| Q2 24 | $0.18 | $-0.14 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.4M | $285.6M |
| 総負債低いほど良い | $3.2B | — |
| 株主資本純資産 | $2.0B | $540.7M |
| 総資産 | $5.9B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 1.63× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $180.4M | — | ||
| Q4 25 | $180.4M | $285.6M | ||
| Q3 25 | — | $262.6M | ||
| Q2 25 | — | $217.8M | ||
| Q1 25 | — | $149.8M | ||
| Q4 24 | — | $144.9M | ||
| Q3 24 | — | $145.0M | ||
| Q2 24 | — | $240.1M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.1B | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $540.7M | ||
| Q3 25 | $2.1B | $505.8M | ||
| Q2 25 | $2.1B | $436.8M | ||
| Q1 25 | $2.1B | $418.6M | ||
| Q4 24 | $2.1B | $403.7M | ||
| Q3 24 | $2.1B | $405.9M | ||
| Q2 24 | $2.1B | $455.8M |
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | $1.4B | ||
| Q3 25 | $5.7B | $1.4B | ||
| Q2 25 | $5.7B | $1.3B | ||
| Q1 25 | $5.8B | $1.3B | ||
| Q4 24 | $5.8B | $1.3B | ||
| Q3 24 | $5.8B | $1.3B | ||
| Q2 24 | $5.8B | $920.8M |
| Q1 26 | 1.63× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.50× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $198.9M | $30.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $186.9M | $29.1M |
| FCFマージンFCF / 売上 | 64.2% | 11.8% |
| 設備投資強度設備投資 / 売上 | 11.1% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 1.65× | 1.10× |
| 直近12ヶ月FCF直近4四半期 | — | $171.4M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $198.9M | — | ||
| Q4 25 | $255.5M | $30.4M | ||
| Q3 25 | $212.8M | $44.1M | ||
| Q2 25 | $265.2M | $75.8M | ||
| Q1 25 | $198.9M | $35.0M | ||
| Q4 24 | $232.7M | $15.9M | ||
| Q3 24 | $184.9M | $12.5M | ||
| Q2 24 | $215.8M | $17.4M |
| Q1 26 | $186.9M | — | ||
| Q4 25 | — | $29.1M | ||
| Q3 25 | — | $38.0M | ||
| Q2 25 | — | $71.8M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | $184.3M | $7.7M | ||
| Q2 24 | $147.2M | $13.0M |
| Q1 26 | 64.2% | — | ||
| Q4 25 | — | 11.8% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 34.0% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 7.1% | ||
| Q3 24 | 68.3% | 5.2% | ||
| Q2 24 | 54.6% | 9.4% |
| Q1 26 | 11.1% | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | 0.0% | 1.3% | ||
| Q3 24 | 0.2% | 3.2% | ||
| Q2 24 | 25.4% | 3.2% |
| Q1 26 | 1.65× | — | ||
| Q4 25 | 4.92× | 1.10× | ||
| Q3 25 | 1.84× | 1.66× | ||
| Q2 25 | 2.13× | 8.87× | ||
| Q1 25 | 1.65× | 2.23× | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 2.51× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AM
| Gathering and compression–Antero Resources | $238.0M | 82% |
| Other | $52.3M | 18% |
| Water handling–third party | $505.0K | 0% |
| Gathering and compression–third party | $295.0K | 0% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
